The acquisition of growth signal self-sufficiency is one of the hallmarks of cancer. We previously reported that the murine IL-9-dependent TS1 cell line gives rise to growth factor-independent clones with constitutive activation of the JAK-STAT pathway.
Introduction
Hematopoiesis is a tightly regulated process in which cytokines dictate fate STAT factors play an active role not only in physiological hematopoiesis, but also in tumoral transformation as uncontrolled STAT activation leads to growth signal selfsufficiency 2 . In hematological malignancies, a common mechanism for constitutive STAT activation is the deregulation of tyrosine kinase activity of the cytokine-receptor complex by gain-of-function alterations affecting the JAK itself or its associated receptor chain. A classical illustration is the activating JAK2 V617F mutation identified in a substantial proportion of patients with chronic myeloproliferative neoplasms (MPN) [3] [4] [5] [6] . Among the JAK2 V617F -negative MPNs, 5% of essential thrombocythemia patients harbor a mutation in the thrombopoietin-receptor (commonly MPL W515L or W515K ) 7 . In acute leukemias from lymphoid (ALL) or myeloid (AML) origin, various JAK1, JAK2 and JAK3 mutations and translocations have been reported [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . In childhood ALL, gain-of-function mutations of the interleukin-7-receptor chain (IL-7Rα)
were described in 10% of cases 19, 20 . JAK inhibitors represent therefore an appealing therapy for leukemia patients since a significant proportion (20-30% in childhood ALL) seems to acquire growth signal self-sufficiency through constitutive activation of the JAK-STAT pathway. Nevertheless, their efficacy has first to be experimentally assessed using preclinical leukemia models.
TS1 is an IL-9-dependent cell line derived from a murine CD4+ T helper clone. While normal T cells require antigen presentation for in vitro growth, repeated biweekly antigen stimulation led to gradual acquisition of IL-9 responsiveness, loss of the need for antigen presentation and emergence of permanent IL-9-dependent cell lines such as TS1 21 . The progressive deregulation undergone by T cells during acquisition of ILFor personal use only. on July 15, 2017 . by guest www.bloodjournal.org From 4 9 responsiveness is somewhat reminiscent of the multistep process leading to cell transformation 22, 23 . Furthermore, the IL-9-responsive TS1 cell line could spontaneously give rise to growth factor (GF)-independent clones that were tumorigenic in vivo 24 . Even though there was no autocrine cytokine production in the supernatants of these GF-independent clones, they showed constitutive phosphorylation of JAK1, JAK3, STAT3 and STAT5 comparable to those induced by IL-9 stimulation in parental TS1 cells 25 .
Because of its T-cell origin and its ability to spontaneously recapitulate the transformation process in vitro, the TS1 model provides us with a unique opportunity to identify T-cell specific oncogenic events potentially implicated in ALL. The aims of our study were first to unravel the genetic mechanisms underlying constitutive JAK-STAT activation in this model and secondly to test the efficacy of short-term and long-term treatment with JAK inhibitors.
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Methods
Cell cutures. TS1 and BW5147 cells were cultured in Iscove-Dulbecco's medium supplemented with 10% fetal bovine serum, 50µM ß-mercaptoethanol, 0.55 mM Larginine, 0.24 mM L-asparagine, 1.25 mM L-glutamine and, for TS1 cells, murine IL-9 (100U/ml) was added. CMK cells were cultured in RPMI medium supplemented with 10% fetal bovine serum.
Stable DNA transfections and selection of clones. WT JAK3 and human IL-9Rα cDNAs were subcloned into the pMX-IRES-CD4 biscistronic retroviral vector upstream of the IRES. WT JAK1 and human γc cDNAs were subcloned into the pMX-IRES-GFP biscistronic retroviral vector upstream of the IRES. The JAK3 (R657H, V674A) and JAK1 (Y652H and A634D) mutants cDNAs were generated using QuickChange XL II site-directed mutagenesis kit (Stratagene). For stable transduction, retroviral supernatants were generated by transient transfection of the BOSC packaging cell line, and used for infection of 0.5 x 10 6 cells as described 26 .
Populations of cells expressing markers were isolated by FACS sorting, using a PEcoupled antibody against hCD4 (#555347, BD Pharmingen) diluted 1/30.
For the selection of GF-independent TS1 clones, IL-9-dependent TS1 cells were washed 3 times in PBS and seeded in 96-well plates at a concentration of 5,000 cells/well in the absence of cytokines. After 1-2 weeks, GF-independent clones were picked up from plates where less than 20% of wells were positive for proliferation, corresponding to a probability of clonality superior to 0.9 according to the Poisson distribution. For the selection of JAK inhibitor-resistant subclones, GF-independent TS1 clones were seeded in 96-well plates at a density of 30,000 cells/well in the presence of 300-600 nM of either pan-JAK inhibitor CMP6 (Calbiochem, cat#420097) TS1, a T lymphocyte cell line, is dependent on IL-9 for proliferation. Removal of IL-9 from the culture medium results in rapid cell death, but few cells occasionally succeed to proliferate independently of GF (at a frequency of approximately 1/20,000). We selected 50 GF-independent TS1 clones. Constitutive STAT5, STAT3, AKT, JAK1 and JAK3 phosphorylation could be observed in all tested IL-9-independent clones, but not in IL-9-starved parental TS1 cells 25 ( Figure S1 ). GFindependent TS1 clones remained sensitive to JAK inhibitors indicating that their proliferation still rely on JAK activity (data not shown).
As both JAK1 and JAK3 were constitutively phosphorylated, we sequenced the JAK1 and JAK3 cDNAs in our collection of 50 GF-independent TS1 clones and found that all of them had acquired a missense point mutation affecting a residue of the pseudokinase or kinase domains of either JAK1, JAK3 or both (Table 1) . A majority of clones harbored a single mutation in one JAK (23 with JAK1 mutation versus 22 with JAK3 mutation), but some clones (5 out of 50) acquired a mutation in both kinases of the IL-9-receptor complex. Altogether, we identified 16 different mutations (6 in JAK1 and 10 in JAK3) affecting 14 residues conserved in mouse and human JAKs. As shown on figure 1, the great majority of mutations map to the interface between pseudokinase and kinase domains of JAK1 and JAK3 that was recently shown to mediate auto-inhibitory mechanism 29 . For 7 out of the 14 residues mutated in our clones, mutations have been also described in human cancers (Supplementary Table S1 ).
Although the total number of mutations of JAK1 and JAK3 was equal (28 JAK1 mutations versus 27 JAK3 mutations), statistics confirm that they were not randomly distributed among experiments suggesting that the relative expansion of the mutated cells occured prior to cytokine withdrawal (Khi 2 -test, p-value <0.05) (Supplementary Table S2 ).
Activated JAK1 and JAK3 mutants cooperate for downstream signal transduction.
The observation that some GF-independent clones had acquired mutations both in JAK1 and JAK3 raised the hypothesis that these mutants might cooperatively contribute to the activation of the signaling pathways necessary for survival and proliferation. To address this hypothesis, we compared the activation of the JAK- CMP6 is an ATP-competitive tyrosine kinase inhibitor that effectively inhibits all JAKs.
In short-term assay, GF-independent proliferation of TS1 clones could be efficiently blocked by CMP6 with IC50 close to 0.1 µM (data not shown). GF-independent TS1
clones harboring primary mutations in either JAK1 (A3, A4) or JAK3 (A6, A11, T4, T15) were seeded in 96 wells-plates in the presence of CMP6 concentrations inhibiting 100% of cell proliferation within 2 days (300-600nM). Upon long-term culture, CMP6-resistant clones arose at a low frequency (1 in 2 million cells). Using
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From this experimental set up, 20 CMP6-selected subclones were obtained from 2 independent TS1 clones with the JAK1 Y652H mutation, and 56 CMP6-selected subclones were obtained from 4 independent clones with 3 different JAK3 mutations (L586S, V674A and T848A). Contrary to our expectations, none of these subclones had acquired any secondary mutations in the originally mutated JAK. By contrast, 16
of the 20 subclones (80%) with a primary JAK1 mutation had acquired a mutation in JAK3, whereas 32 of the 56 subclones (57%) with a primary JAK3 mutation had acquired a mutation in JAK1 ( Table 2 ).
Most of the secondary mutations affect the homologous residues F958 in JAK1 and These experiments show that acquiring a secondary activating mutation in another JAK allows for increased resistance to JAK inhibitors that block both JAKs. However, a striking observation from the CMP6-selected subclones described in table 2, is that Complete titration allowing to assess IC50 concentrations confirmed that the intrinsic ability of CMP6 to inhibit STAT5 phosphorylation is not altered in the double heterozygous condition (JAK1 homozygous: 61nM; JAK3 homozygous: 365nM; double heterozygous: 250nM) (data not shown). These results support the hypothesis that acquiring a secondary mutation in the JAK partner from heterodimeric cytokine receptor complex activates the pathway further than becoming homozygous. In addition, when basal STAT5 activity is boosted to strong levels by the 2 mutated JAKs, CMP6 still interferes with STAT5 activation, but higher concentrations would be required to reach a critical threshold.
Secondary mutations in JAK3 confer increased resistance to a JAK1-specific inhibitor.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From It is well known that the transforming effect of an active JAK mutant depends on its association with cytokine receptor chains allowing homo-or heterodimerization with another JAK and subsequent cross-phosphorylation 31, 32 . For instance, an active JAK3 mutant requires a functional JAK1 partner for constitutive signaling 33 . When CMP6, a pan-JAK inhibitor, was used to select resistant TS1 subclones, selective pressure was exerted on both the mutated JAK and its partner, and secondary mutations in the JAK partner provide a selective advantage. We thus wondered whether the same process of selection would occur if only JAK1 activity is blocked with a more selective kinase inhibitor such as Ruxolitinib, which is at least 100 times less potent on JAK3 34 .
To address this question, we seeded 6 different GF-independent TS1 clones harboring the primary JAK1 Y652H mutation in the presence of Ruxolitinib. Ruxolitinibresistant clones arose at a frequency comparable to what was observed during selection with CMP6. JAK1 and JAK3 cDNA sequencing revealed that 44 out of 53
Ruxolitinib-selected TS1 subclones had acquired secondary mutations in the JAKs.
25 of them (57%) had a secondary mutation in JAK3, similar to the selection with CMP6, although Ruxolitinib is not supposed to block JAK3. However, contrasting with CMP6 selection, 18 of the Ruxolitinib-selected subclones had a secondary mutation in JAK1, either within or outside the ATP-binding pocket, including 4 subclones that became homozygous for the JAK1 Y652H mutation (Table 3) . Finally, one of the Ruxolitinib-selected subclones had acquired 2 secondary mutations, JAK1 F958S and JAK3 R840C . As for the primary mutations, the observation of a single predominant mutation within an experiment (e.g. JAK3 Y824D in A3) is consistent with the hypothesis of pre-existing secondary mutations before selective pressure with the inhibitor.
Altogether, our results indicate that when one JAK from a heterodimeric cytokine receptor complex is specifically targeted by a tyrosine kinase inhibitor, resistance can be conferred either by a secondary mutation in the other JAK partner or by a secondary activating mutation in the same JAK. In both cases, and in line with CMP6-selected clones, the secondary mutations are not restricted to the ATPbinding pocket.
Discussion
In the present study, we describe a new mechanism of resistance to JAK kinase inhibitors. We show that 2 concomitant spontaneous activating mutations in endogenous JAK1 and JAK3 cooperatively activate the JAK-STAT pathway leading to increased resistance to CMP6 or Ruxolitinib. Interestingly, such resistance could be conferred by combining mutations that do not affect the sensitivity of cells to JAK inhibitors when present individually.
In our series of subclones selected in the presence of tyrosine kinase inhibitors (TKI), TKI-resistance was not primarily conferred by impairing drug binding to the oncogenic kinase, but rather by increasing the activity of the heterodimeric JAK/receptor complex. Indeed, secondary mutations associated with CMP6-resistance did not affect the originally mutated JAK. In addition, the secondary mutations in the JAK partner observed here were previously described as activating mutations per se, associated with oncogenesis in vitro and in vivo (Supplementary Table 1 , the c-Kit T670I mutation in gastrointestinal stromal tumors 36 and the EGFR T790M in lung adenocarcinomas 37 . There are other substitutions described in
Imatinib-resistant CML patients that are not located near the ATP-binding site of and are therefore considered as gain-of-function mutations [39] [40] [41] . Using high-sensitivity detection methods, BCR-ABL Imatinib-resistant mutations could be detected at low level in a considerable fraction (12,5-22%) of untreated CML patients indicating that resistant mutations can preexist to the onset of treatment [42] [43] [44] . Noticeably, the majority of pre-treatment secondary mutations are gain-of-function substitutions, suggesting that they might confer a slight proliferation advantage over parental BCR-ABL in the absence of Imatinib, and expand during treatment under selective pressure 43, 44 . In our TS1 model, a similar selection process of pre-existing activating JAK1 and JAK3 mutations might take place. During culture, spontaneous mutations occur randomly throughout the TS1 cell genome and some of them activate JAK1 or JAK3. GF-independent cells with a single activating JAK mutation that acquired by chance a secondary activating mutation in the JAK partner activate further the JAK-STAT pathway, which provides a subtle growth advantage allowing for their persistence and slow relative expansion in the culture. JAK inhibitor selection pressure will foster the emergence of these double mutated cells because their higher basal level of JAK-STAT activation will raise the threshold inhibitor concentration needed to induce apoptosis. The hypothesis that the secondary mutations preexisted before selection with JAK inhibitors is supported by the fact that, in several experiments, a majority of TKI-resistant subclones showed the same secondary mutation (Tables 2 and 3) .
In ALL patients, activating mutations in either JAK1, JAK3 and IL-7Rα have been Supplementary table 3 ) 46, 18, 47, 48 .
Secondary mutations are not the exclusive way for transformed cell to survive in the presence of TKIs, and some of our TKI-resistant subclones did not show any (Tables 2 and 3) . It is worth to notice that the 2 types of JAK inhibitor-selected subclones (mutated and non-mutated) can not be distinguished based on their sensitivity to inhibitors. All JAK inhibitor-selected subclones do not exhibit an absolute resistance but rather a relative shift in sensitivity ( figures 3A and 3B) . This gives us a rationale to speculate that the unknown mechanism allowing the non-mutated subclones to proliferate in the presence of inhibitor still relies on JAK activity. However, no mutation in JAK2 and TYK2 were found in 20 non-mutated subclones analyzed so far. Alternatively, a shift in oncogene addiction from the JAK-STAT towards PI3K or MAP kinases pathways is not excluded.
In JAK2
V617F -transformed cell lines treated with gradually increasing doses of Ruxolitinib in vitro, JAK2 overexpression was associated with a reversible stage of so-called JAK2 inhibitor persistence 49 . In our laboratory, we observed a similar increase in the expression of JAK1 mRNA in BAF3 cells expressing the endogenous JAK1 F958V mutant when cells were cultured in the presence of CMP6 30 . However, we did not observe any significant increase in JAK1 and JAK3 mRNA expression levels for our TKI-resistant subclones without secondary mutations in JAKs (data not shown). An alternative resistance mechanism might result from loss of negative regulators of the pathway, such as PTPN2, a phosphatase active on phosphotyrosine residues located in the activation loop of JAK1 and JAK3 and necessary for full kinase activity 50 . Deletions of PTPN2 were identified in 6% of T-ALL cases 51 and knock-down of PTPN2 reduced sensitivity of cells to JAK inhibition 52 .
Because of its high versatility, the TS1 model described here represents an invaluable tool for further studies aiming at unraveling new secondary mutation in such genes that might cause increased TKI-resistance. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
